What prostate cancer patient population would benefit from a brachytherapy boost after EBRT without the use of ADT?
Based on recent data published suggesting an OS advantage to the addition of ADT vs. brachytherapy boost to EBRT (Jackson et al., PMID 32396488), it is unclear what patients would be appropriate for EBRT+BT without ADT.
1 Answer
Mednet MemberInvited Expert
Radiation Oncology · Case Western Reserve University/ University Hospitals Seidman Cancer Center
Answered on
The paper referenced in the question for better or worse is the best evidence we have regarding the benefit we can expect from a brachy boost, the benefit we can expect from the addition of ADT to EBRT, and if you were to compare EBRT+ADT vs EBRT+brachy. It shows that adding ADT has an OS benefit co...
Join for free or sign in to see the full answer